LabCorp, one of the world's leading healthcare diagnostic companies, has agreed to buy Sequenom for $371 million.
San Diego-based Sequenom was one of the pioneers in developing non-invasive genetic tests.
It suffered a setback last year, when a federal appeals court invalidated the company’s patent for a prenatal DNA test. The U.S. Supreme Court declined to review the case last month.
Sequenom’s CEO Dirk van den Boom said becoming part of LabCorp will allow the company to reach a much broader market.
LabCorp officials said their purchase of the company is a highly strategic move. Officials say Sequenom’s best-in-class offerings and strong research and development pipeline perfectly compliment LabCorps’ test menu.
LabCorp has more than 48,000 employees worldwide.